Tyra Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 193.19K shares, a 34.59% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 1.03M shares, a 231.50% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 388.16K shares, a 142.34% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 63.65K shares, a 33.46% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 904.99K shares, a 52.10% increase from fiscal 2024.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 594.99K shares, a 45.76% increase from fiscal 2023.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 408.21K shares, a 679.66% increase from fiscal 2022.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 52.36K shares, a 94.04% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 193.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 1.67M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 1.03M shares 10-Q · filed 2026-05-13 | 1.62M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 388.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 904.99K shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 63.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 677.01K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 143.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 709.01K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 309.65K shares 10-Q · filed 2025-05-08 | 812.36K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 160.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 594.99K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 95.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 478.48K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 246.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 419.65K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 92.28K shares 10-Q · filed 2024-05-09 | 403.26K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 43.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 408.21K shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 36.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 366.15K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 230.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 363.41K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 97.23K shares 10-Q · filed 2023-05-04 | 148.15K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 1.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 52.36K shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 34.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 51.28K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 15.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | |
| 2022-03-31 | 1.43K shares 10-Q · filed 2022-05-05 | |
| 2021-12-31 | 522.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 877.86K shares 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |